Use of Ovatodiolide against SARS-CoV-2

Patent metadata

Field	Value
Publication number	US-12403125-B2
Application number	US-202017996226-A
Country	US
Kind code	B2
Filing date	Apr 17, 2020
Priority date	Apr 17, 2020
Publication date	Sep 2, 2025
Grant date	Sep 2, 2025

Abstract

A compound of Formula I compound—Ovatodiolide which is safe and effective to use in a pharmaceutical composition for inhibition of SARS-CoV-2 is provided. The pharmaceutical composition comprising a safe and effective amount of a compound of Formula I compound—Ovatodiolide or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, which has great potential to treat SARS-CoV-2 induced COVID-19 based on a safe and effective amount of a compound of Formula I compound—Ovatodiolide.

First claim

What is claimed is:

1. A method for inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which comprises administering a safe and effective amount of Formula I compound—Ovatodiolide or a safe and effective amount of structural isomer of the Formula I compound—Ovatodiolide to a subject,

2. The method of claim 1 , wherein the safe and effective amount of the Formula I compound—Ovatodiolide or the safe and effective amount of structural isomer of the Formula I compound—Ovatodiolide is combined with a pharmaceutically acceptable salt thereof or a carrier to form a composition.

3. The method of claim 2 , wherein the composition can be used for preventing or treating diseases caused by SARS-CoV-2.

4. The method of claim 2 , wherein the composition can be used for preventing or treating coronavirus disease 2019 (COVID-19).

5. The method of claim 1 , wherein the Formula I compound—Ovatodiolide is a natural compound as a component prepared by extracting Anisomeles indica D. Kuntze with an organic solvent and separating and purifying by a chromatographic column, or is a synthetic compound having the same structure as the natural Formula I compound—Ovatodiolide as a component prepared by chemical synthesis.

6. The method of claim 2 , wherein the safe and effective amount for an adult with body weight of 60 kg is less than 480 mg per day orally, and administered continuously for less than 28 days.

7. The method of claim 2 , wherein the safe and effective amount for an adult with body weight of 60 kg is from 20 mg to 40 mg per day orally, and administered continuously for 7 to 14 days as appropriate.

8. A method for inhibiting coronavirus which comprises administering a safe and effective amount of Formula I compound—Ovatodiolide, or a safe and effective amount of structural isomer of the Formula I compound—Ovatodiolide to a subject.

Assignees

• Univ Peking Shenzhen Graduate School
• Cns Biotek Corp
• Gansu Evergreen Pharmaceuticals Co Ltd

Inventors

• Yang Zhen
• Tzeng Yew-Min
• Zhang Linqi
• Quan Junmin
• Chang Qing
• Zhang Qi
• Lee Chien-Ming

Classifications

• A61K2236/39

  Complex extraction schemes, e.g. fractionation or repeated extraction steps · CPC title

• A61K2236/35

  Extraction with lipophilic solvents, e.g. Hexane or petrol ether · CPC title

• A61K36/53

  Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title